Enhancing Surgical Precision with Fluorescence Imaging in Cancer Care

Abstract

Fluorescence-guided surgery (FGS) is an innovative intraoperative imaging modality increasingly recognized for its potential to enhance tumor visualization, improve surgical precision, and optimize oncologic outcomes. Leveraging fluorescent dyes and near-infrared (NIR) imaging technologies, FGS enables real-time differentiation between malignant and normal tissues. This review synthesizes current evidence, discusses the mechanisms and practical applications of FGS, and highlights recent advances, guideline recommendations, and future prospects in the context of surgical oncology and other clinical domains. Key considerations include the epidemiology of cancers benefiting from FGS, disease mechanisms underlying its value, patient selection, and integration into current therapeutic paradigms.

Introduction

Intraoperative visualization of tumor margins remains a critical challenge in achieving complete resection and reducing recurrence rates for many malignancies. Traditional imaging modalities, while valuable, often lack the spatial or real-time resolution required for precise intraoperative guidance. Fluorescence-guided surgery represents a significant advancement, utilizing targeted or non-targeted fluorescent agents in combination with specialized imaging systems to provide surgeons with enhanced contrast between diseased and healthy tissues. The clinical adoption of FGS has grown in parallel with technological advances and a deeper understanding of tumor biology, positioning it as a promising tool for improving surgical outcomes across a range of indications.

Epidemiology / Disease Burden

The global burden of cancer continues to rise, with over 19 million new cases and nearly 10 million deaths annually. Surgical resection remains the cornerstone of curative therapy for most solid tumors, including gliomas, breast, colorectal, and hepatobiliary cancers. Incomplete tumor removal, however, is associated with higher rates of local recurrence and poorer survival. FGS has proven particularly impactful in high-risk malignancies such as glioblastoma multiforme where maximal safe resection directly correlates with survival and in sentinel lymph node mapping for breast cancer and melanoma. The epidemiological imperative for more precise surgical tools underpins the need for FGS integration in standard practice.

Pathophysiology

FGS exploits the pathophysiological differences between malignant and non-malignant tissues, including altered vascular permeability, metabolic activity, and molecular expression. Tumors often exhibit the enhanced permeability and retention (EPR) effect, allowing fluorescent molecules, especially those in the NIR spectrum, to accumulate preferentially in neoplastic tissues. Targeted agents such as those conjugated to antibodies or peptides bind to tumor-specific markers like EGFR, folate receptor, or HER2, further increasing specificity. Non-targeted agents, such as indocyanine green (ICG), are used for lymphatic mapping and perfusion assessment due to their favorable pharmacokinetics and safety profiles.

Risk Factors

Patient selection for FGS depends on multiple risk factors, including tumor histology, location, prior treatments, and potential for incomplete resection. High-grade gliomas, head and neck cancers, and hepatobiliary malignancies with indistinct margins are prime candidates. Additional risk factors influencing FGS efficacy include the presence of blood-brain barrier disruption, tumor vascularity, and individual pharmacodynamics of the fluorescent agent. Adverse reactions to dyes, while rare, must be considered especially in patients with allergies or hepatic/renal impairment.

Clinical Features

The clinical features prompting FGS utilization include tumors with ill-defined or infiltrative margins, those located adjacent to critical structures, or lesions necessitating lymphatic mapping for staging purposes. Real-time intraoperative feedback from FGS allows for dynamic assessment of resection margins, detection of residual disease, and identification of sentinel lymph nodes. Surgeons can adjust their approach on the basis of fluorescence intensity, thereby reducing the likelihood of both under- and over-resection, which is essential for preserving function and minimizing morbidity.

Diagnosis

Preoperative planning involves imaging modalities such as MRI, CT, and PET to delineate tumor extent. FGS complements these by providing intraoperative diagnostic clarity. Fluorescent probes, administered systemically or locally, illuminate neoplastic tissue upon excitation by a specific wavelength. The choice of probe targeted vs. non-targeted depends on tumor biology and surgical goals. Integration with neuronavigation or laparoscopic systems further augments diagnostic precision. Quantitative analysis of fluorescence signals can be used to guide biopsies and immediate histopathological assessment, enhancing diagnostic yield.

Treatment & Management

FGS is most commonly applied during surgical resection of malignant tumors. Agents such as 5-aminolevulinic acid (5-ALA) in neuro-oncology, ICG in hepatobiliary and colorectal surgery, and methylene blue in parathyroid identification are now routinely used in specialized centers. Perioperative protocols require multidisciplinary coordination, including timing of dye administration, intraoperative imaging setup, and interpretation of fluorescence signals. Postoperative management may involve correlation of fluorescence-guided margins with histopathology to validate complete resection and inform adjuvant therapy decisions.

Recent Advances / Emerging Therapies

Recent advances in FGS include the development of next-generation targeted fluorophores with higher specificity and improved safety profiles. Agents targeting PSMA, VEGF, and integrins are under clinical investigation, particularly for prostate, ovarian, and colorectal cancers. Multispectral and hybrid imaging modalities now enable simultaneous visualization of multiple fluorescent agents, facilitating more complex surgical decision-making. Artificial intelligence-based image analysis is being explored to further enhance intraoperative interpretation and automate margin assessment. The emergence of activatable probes fluorescent only in the presence of specific tumor-associated enzymes offers the potential for even greater selectivity and reduced background signal.

Guideline Recommendations

Professional societies, including the European Association of Neuro-Oncology and the Society of Surgical Oncology, recommend FGS for selected indications, such as high-grade glioma resection and sentinel lymph node mapping in breast cancer. Guidelines emphasize the importance of institutional experience, appropriate patient selection, and adherence to standardized protocols for dye administration and imaging. Ongoing clinical trials are likely to expand the range of indications and support stronger, evidence-based recommendations for broader adoption of FGS in surgical practice.

Conclusion

Fluorescence-guided surgery represents a paradigm shift in intraoperative visualization, offering significant improvements in tumor detection, resection accuracy, and patient outcomes. Integration of FGS into routine surgical workflows requires multidisciplinary collaboration, ongoing technological innovation, and adherence to emerging clinical guidelines. As clinical evidence continues to accumulate and new fluorophores are developed, FGS is poised to become an indispensable tool in the surgical armamentarium, with broad applications across oncology and other fields demanding high-precision surgery.